

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fujian Haixi Pharmaceuticals Co., Ltd.
福建海西新藥創制股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2637)

VOLUNTARY ANNOUNCEMENT
LAUNCH OF PHASE III OSTEOSARCOMA CLINICAL TRIAL
FOR C019199 TABLETS BY HAIXI PHARMACEUTICALS

This announcement is made by Fujian Haixi Pharmaceuticals Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Haixi Pharmaceuticals**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The Board of Directors (the “**Board**”) of the Company is pleased to announce that the Phase III clinical trial of C019199 tablets, an independently developed drug of the Company, has been officially initiated for the treatment of osteosarcoma after failure of at least two prior lines of therapy (CTR20261818). Relevant information has been published on the Drug Clinical Trial Registration and Information Disclosure Platform of the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) of China.

This randomized, controlled, open-label, multicenter Phase III study (Protocol No.: HXP019-CTPIII-02) is designed to evaluate the efficacy and safety of C019199 tablets versus gemcitabine plus docetaxel in the target patients. A total of approximately 120 subjects are expected to be enrolled across multiple clinical research centers nationwide. Progression-free survival (PFS) as assessed by the blinded independent review committee (BIRC) will serve as the primary endpoint, and other multi-dimensional indicators including overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety, will serve as secondary endpoints.

About C019199 Tablets

C019199 tablets is a first-in-class, multi-target tumor immunomodulator developed by Haixi Pharmaceuticals based on its proprietary MultiSel-Opt small-molecule innovative drug R&D platform. As a common malignant bone tumor that threatens the lives and health of adolescents and young patients, osteosarcoma has a poor prognosis following relapse, metastasis and second-line treatment failure, representing a significant unmet medical need in current clinical practice. The initiation of the Phase III clinical trial for C019199 tablets marks a critical milestone for the Group's innovative pipeline in the treatment of advanced osteosarcoma and is expected to provide patients with a novel therapeutic option.

Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board

Fujian Haixi Pharmaceuticals Co., Ltd.

Dr. Kang Xinshan

Executive Director, Chairman and General Manager

Hong Kong, 9 July 2026

As of the date of this announcement, the Board comprises (i) Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Mr. Li Junqing as executive Directors; (ii) Mr. Wang Xinkun and Mr. Xu Dong as non-executive Directors; and (iii) Ms. Wang Shan Shan, Ms. Pu Meiting and Mr. Lin Bin as independent non-executive Directors.